Propanc Biopharma (PPCB) Current Assets (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Current Assets of $7.7 million for Q4 2025, up 42754.34% year-over-year from N/an in Q4 2024, and down 12.06% quarter-over-quarter from $8.8 million in Q3 2025.
Propanc Biopharma (PPCB) Current Assets (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Current Assets for 15 consecutive years, with $7.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets rose 42754.34% year-over-year to $7.7 million; the TTM figure through Dec 2025 stood at $7.7 million (up 42754.34% YoY), while the FY2025 annual figure was $8.4 million, up 32732.11% from the prior year.
- Current Assets declined to $7.7 million in Q4 2025 per PPCB's latest filing, from $8.8 million in the prior quarter.
- Across five years, Current Assets topped out at $9.7 million in Q1 2025 and bottomed at $6596.0 in Q2 2021.
- Historically, Current Assets has averaged $1.8 million across 5 years, with a median of $55317.0 in 2021.
- Annual changes were most pronounced in 2024 — Current Assets slumped 91.47% — and 2025, when it jumped 75637.47%.
- Propanc Biopharma's Current Assets stood at $84878.0 in 2021, then tumbled by 36.11% to $54226.0 in 2022, then jumped by 288.79% to $210824.0 in 2023, then plunged by 91.47% to $17984.0 in 2024, then jumped by 42754.34% to $7.7 million in 2025.
- Business Quant data shows PPCB's Current Assets at $7.7 million in Q4 2025, $8.8 million in Q3 2025, and $8.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 7.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.71 Mn |
| Sep 30, 2025 | 8.76 Mn |
| Jun 30, 2025 | 8.35 Mn |
| Mar 31, 2025 | 9.74 Mn |
| Dec 31, 2024 | 17,984.00 |
| Sep 30, 2024 | 21,534.00 |
| Jun 30, 2024 | 25,441.00 |
| Mar 31, 2024 | 12,855.00 |
| Dec 31, 2023 | 210,824.00 |
| Sep 30, 2023 | 145,804.00 |
| Jun 30, 2023 | 19,039.00 |
| Mar 31, 2023 | 96,575.00 |
| Dec 31, 2022 | 54,226.00 |
| Sep 30, 2022 | 37,862.00 |
| Jun 30, 2022 | 15,030.00 |
| Mar 31, 2022 | 144,506.00 |
| Dec 31, 2021 | 84,878.00 |
| Sep 30, 2021 | 56,408.00 |
| Jun 30, 2021 | 6,596.00 |
| Mar 31, 2021 | 18,518.00 |